Cargando…
Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
BACKGROUND: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes a...
Autores principales: | Kanchanasurakit, Sukrit, Santimaleeworagun, Wichai, McPherson, Charles E., Piriyachananusorn, Napacha, Boonsong, Benjawan, Katwilat, Papanin, Saokaew, Surasak |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779995/ https://www.ncbi.nlm.nih.gov/pubmed/33124216 http://dx.doi.org/10.3947/ic.2020.52.4.516 |
Ejemplares similares
-
418. Fosfomycin Dosing Regimens for The Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Receiving Continuous Renal Replacement Therapy: a Monte Carlo Simulation
por: Kanchanasurakit, Sukrit, et al.
Publicado: (2022) -
Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised patients with mild coronavirus disease 2019: A retrospective cohort study
por: Tanwettiyanont, Jeeranan, et al.
Publicado: (2022) -
Effectiveness of thiamine therapy in mortality rate in patients with septic shock: A systematic review and meta-analysis
por: Kanchanasurakit, Sukrit, et al.
Publicado: (2021) -
Antimicrobial Susceptibility among Colistin, Sulbactam, and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii
por: Leelasupasri, Sombat, et al.
Publicado: (2018) -
Chlorogenic acid in green bean coffee on body weight: a systematic review and meta-analysis of randomized controlled trials
por: Kanchanasurakit, Sukrit, et al.
Publicado: (2023)